

News Release

**License & Supply Agreement with Laboratorio Elea Phoenix S.A.
on Infliximab Biosimilar in Argentine market**

Tokyo, Japan, June 17, 2021 – Nichi-Iko Pharmaceutical Co., Ltd. (Head office: Toyama Prefecture; President and CEO: Yuichi Tamura; hereinafter, “Nichi-Iko”) and Laboratorio Elea Phoenix S.A. (Head office: Argentina, hereinafter, “Elea”) announced that they entered into a license and supply agreement of Infliximab biosimilar product, TNF α monoclonal antibody formulation (hereinafter, “the Product”) for Argentine market, and Elea filed the application for product registration to the Argentine health regulatory agency.

Elea has actively engaged in development of biosimilar products and has already marketed the two first biosimilar products in Argentine market, achieving top market shares on these products. With this strong business partnership and agreement, Nichi-Iko aims to develop and to tap into an Infliximab biologics market in Argentina promptly. And leveraging the approved data in Japan, Elea already has filed the application of this Product to the Argentine health regulatory agency, aiming at obtaining an approval in 2021. In addition, Nichi-Iko plans to supply the Product from its US subsidiary Sagent Pharmaceuticals, Inc. Raleigh plant in the future.

As a global comprehensive manufacturer of generic pharmaceuticals, serving the patients suffering from illnesses with compassion, Nichi-Iko provides needed pharmaceutical products to patients around the world, by further globalizing our product development readiness and expanding product line-ups, in conformance to the international regulatory standards.

[Notes]

Laboratorio Elea Phoenix S.A. (Elea)

Elea was established in 1939 and markets approximately 400 products including different biologics, primary care and OTC products in Argentina.

Elea is strongly positioned in the Argentine market, having the largest sales force in the country. Elea especially focuses on strengthening of biosimilar products and markets Rituximab biosimilar and Bevacizumab biosimilar not only in Argentina but also expanding into other countries in Latin America, by the collaboration with its group company mAbxience Research, S.L, which is a business partner of Nichi-Iko as well.

Inquiries E-mail: ir@nichiiko.co.jp